Stocklytics Platform
Asset logo for symbol BIVI
BioVie
BIVI50
$1.90arrow_drop_down8.41%-$0.17
Penny Stock
Asset logo for symbol BIVI
BIVI50

$1.90

arrow_drop_down8.41%

Performance History

Chart placeholder
Key Stats
Open$2.05
Prev. Close$2.08
EPS-5.08
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap$33.75M
PE Ratio-
LOWHIGH
Day Range1.88
2.23
52 Week Range1.04
58.20
Ratios
Revenue-
EBITDA Margin %-
EPS-5.08

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About BioVie (BIVI)

BioVie Inc. (BIVI) is a biopharmaceutical company focused on the development and commercialization of innovative therapies for patients with liver diseases. The company's lead product candidate is BIV201, a continuous infusion formulation of terlipressin, which is being developed for the treatment of refractory ascites due to liver cirrhosis. Ascites is a serious complication of liver disease and is characterized by the accumulation of fluid in the abdominal cavity. It can lead to significant morbidity and mortality if left untreated. BIV201 has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of ascites.
BioVie is currently conducting a Phase 2b clinical trial evaluating BIV201 in patients with refractory ascites. The trial is designed to evaluate the safety and efficacy of BIV201 compared to placebo. Preliminary data from the trial has shown promising results, with BIV201 demonstrating a significant reduction in ascites volume compared to placebo. The company is optimistic about the potential of BIV201 to address an unmet medical need in the treatment of refractory ascites.
Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Cuong Viet Do M.B.A., MBA
Headquarters
Carson City
Employees
18
Exchange
NASDAQ
add BioVie to watchlist

Keep an eye on BioVie

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is BioVie's (BIVI) price per share?

The current price per share for BioVie (BIVI) is $1.9. The stock has seen a price change of -$0.18 recently, indicating a -8.41% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for BioVie (BIVI)?

For BioVie (BIVI), the 52-week high is $58.2, which is 2.96K% from the current price. The 52-week low is $1.04, the current price is 82.69% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is BioVie (BIVI) a growth stock?

BioVie (BIVI) has shown an average price growth of -4.38% over the past three years. It has received a score of 35 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying BioVie as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is BioVie (BIVI) stock price performance year to date (YTD)?

As of the latest data, BioVie (BIVI) has a year-to-date price change of -86.13%. Over the past month, the stock has experienced a price change of -38.91%. Over the last three months, the change has been -32.14%. Over the past six months, the figure is -59.53%.
help

Is BioVie (BIVI) a profitable company?

BioVie (BIVI) has a net income of -$32.12M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$32.18M. Furthermore, the EBITDA is -$31.95M.
help

What is the market capitalization of BioVie (BIVI)?

BioVie (BIVI) has a market capitalization of $33.76M. The average daily trading volume is 1.99, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level